PPD Confirms Takeda’s NDA Submission Of Alogliptin (highly Selective DPP-4 Inhibitor For The Treatment Of Type 2 Diabetes) In Japan

PPD, Inc. (NASDAQ:PPDI) today confirmed that Takeda Pharmaceutical Company Limited has submitted a new drug application for alogliptin, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, to the Ministry of Health, Labour and Welfare in Japan. PPD partnered with Takeda to develop the compound.

More: continued here

Filed under: Diabetes on October 3rd, 2008